What's the Half-Life of Adamax? (Peptide Stability Guide)

Adamax (GHRP-2, or Growth Hormone Releasing Peptide-2) has a plasma half-life of approximately 25–30 minutes following subcutaneous administration. One of the shortest elimination windows among commonly used research peptides. That's not a typo. While semaglutide lingers for five days and tirzepatide for nearly a week, Adamax clears from circulation in under an hour. This ultra-short duration isn't a design flaw. It's a deliberate pharmacokinetic profile that allows for precise, pulsatile GH release studies without multi-day carryover effects.

Our team has worked with researchers using growth hormone secretagogues across multiple study designs. The single most common protocol error we see isn't contamination or incorrect dosing. It's misunderstanding what a 30-minute half-life means for timing, storage stability post-reconstitution, and baseline washout periods between dosing cycles.

What's the half-life of Adamax, and why does it matter for research protocols?

Adamax (GHRP-2) has a plasma half-life of 25–30 minutes after subcutaneous injection, meaning the peptide's active concentration drops by 50% every half-hour. Within two hours, more than 93% of the administered dose has been eliminated. This rapid clearance allows researchers to design studies with multiple daily dosing windows without accumulation. But it also means reconstituted solutions have limited stability at room temperature and require refrigerated storage between uses.

What Adamax's Half-Life Actually Measures

The 25–30 minute plasma half-life refers to the time required for circulating Adamax concentration to drop by 50% following peak absorption. This is elimination half-life. Not duration of action. The growth hormone pulse triggered by GHRP-2 administration can persist for 90–120 minutes even after the peptide itself has cleared, because GH secretion involves a cascade: Adamax binds to ghrelin receptors on pituitary somatotrophs, triggering intracellular cAMP signaling that leads to GH vesicle release. Once that cascade starts, it doesn't stop the moment Adamax clears. The biological effect outlasts the peptide's presence.

This creates a meaningful distinction for research design. Studies measuring acute GH response typically collect blood samples at 15, 30, 60, and 90 minutes post-administration. Peak GH levels usually occur 30–45 minutes after injection, well after Adamax plasma levels have already begun declining. Pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body) operate on different timescales here.

The short half-life also explains why multi-dose-per-day protocols are standard in GHRP-2 research. A single morning injection doesn't maintain elevated GH signaling through the evening. Researchers studying sustained effects typically dose 2–3 times daily, spaced at least 4–6 hours apart to avoid receptor desensitization while ensuring each pulse fully clears before the next.

How Adamax's Half-Life Compares to Other Peptides

Context matters. Semaglutide's 165-hour half-life allows weekly dosing. Tirzepatide sits around 120 hours. Even shorter-acting GLP-1 agonists like liraglutide have a 13-hour half-life, permitting once-daily administration. GHRP-2's 30-minute window places it in a completely different pharmacokinetic class. Closer to insulin analogues than to metabolic peptides.

The comparison underscores a design principle: peptides engineered for long-term metabolic regulation use structural modifications (like fatty acid chains or Drug Affinity Complexes) to extend circulation time. Growth hormone secretagogues like GHRP-2 are intentionally short-acting to mimic natural pulsatile GH release. The body doesn't secrete growth hormone continuously; it releases it in discrete pulses throughout the day, peaking during deep sleep. Adamax replicates that pattern.

Reconstituted Stability vs Plasma Half-Life

This is where confusion compounds. Plasma half-life (how long the peptide stays active in circulation) is not the same as solution stability (how long a reconstituted vial remains potent). Adamax's 30-minute plasma clearance doesn't mean your reconstituted vial degrades in 30 minutes. Peptide stability in bacteriostatic water depends on temperature, pH, and exposure to light and air.

Reconstituted GHRP-2 stored at 2–8°C (refrigerated) maintains >95% potency for 28 days when prepared with sterile bacteriostatic water containing 0.9% benzyl alcohol. At room temperature (20–25°C), that window drops to 48–72 hours before measurable degradation begins. Freeze-thaw cycles accelerate breakdown. Each cycle can reduce potency by 5–10%, which is why single-use aliquots are standard practice in research settings.

Unreconstituted lyophilized Adamax powder is far more stable. Stored at −20°C in a sealed vial with minimal air exposure, the dry peptide retains full potency for 24–36 months. This is the form we supply at Real Peptides. Lyophilized in sterile vials, third-party tested for purity and exact amino acid sequencing. Reconstitute only what you'll use within a 28-day research window.

The practical implication: don't confuse how fast the peptide clears the bloodstream with how long your prepared solution stays viable. They're governed by completely different mechanisms. Enzymatic degradation in plasma versus hydrolytic and oxidative breakdown in solution.

What's the Half-Life of Adamax?: Research Peptide Comparison

Key Takeaways

• Adamax (GHRP-2) has a plasma half-life of 25–30 minutes, with over 90% eliminated within two hours of subcutaneous administration.
• The short half-life allows researchers to dose 2–3 times daily without accumulation, mimicking natural pulsatile growth hormone release patterns.
• Reconstituted Adamax stored at 2–8°C maintains potency for 28 days. Plasma clearance speed and solution stability are separate parameters.
• Peak growth hormone response occurs 30–45 minutes post-injection, outlasting the peptide's plasma presence due to downstream signaling cascades.
• Unreconstituted lyophilized GHRP-2 stored at −20°C retains full potency for 24–36 months, far exceeding the stability of pre-mixed solutions.
• Frequent freeze-thaw cycles degrade reconstituted peptides by 5–10% per cycle. Prepare single-use aliquots for precision research protocols.

What If: Adamax Dosing Scenarios

What If I Need to Dose Adamax More Than Once Daily?

Space doses at least 4–6 hours apart. The 30-minute half-life means plasma levels return to baseline within 2 hours, but pituitary GH secretion takes longer to reset. Dosing every 2–3 hours can cause receptor desensitization, blunting subsequent GH pulses. Research protocols typically use morning (fasted), midday, and pre-sleep dosing windows to align with natural GH secretion patterns while avoiding overlap.

What If My Reconstituted Adamax Was Left at Room Temperature Overnight?

If the vial was at 20–25°C for 8–12 hours, expect 10–15% potency loss. This isn't catastrophic for a single occurrence, but it compounds with each exposure. Refrigerate immediately and use within 14 days instead of the standard 28-day window. If the solution was exposed to temperatures above 30°C or left out for more than 24 hours, discard it. Heat-induced denaturation is irreversible and cannot be detected visually.

What If I'm Designing a Multi-Week Study Protocol?

Adamax's rapid clearance makes it ideal for washout-free crossover designs. A 24-hour washout period is sufficient to eliminate all residual peptide and allow baseline GH levels to normalize. For comparison, studies using modified-release GH secretagogues like CJC-1295 with DAC require 2–3 week washout periods. The short half-life also reduces confounding variables. Each dose is an independent stimulus, not part of a sustained elevation.

The Unvarnished Truth About Adamax's Half-Life

Here's the honest answer: the 30-minute half-life is exactly why GHRP-2 remains relevant in 2026 despite newer, longer-acting alternatives. Researchers don't want a GH secretagogue that lingers for days. That would make it impossible to isolate acute effects, control for circadian variation, or run multiple dosing conditions in a single study period. The short clearance window is the feature, not a limitation.

Every "next-generation" secretagogue with extended half-life sacrifices experimental flexibility. If you're studying receptor binding kinetics, comparing dose-response curves, or measuring how GH pulses interact with feeding windows, you need a peptide that clears fast and clears completely. Adamax delivers that. The compounds marketed as improvements. Sustained-release formulations, oral mimetics with 6-hour half-lives. Solve a clinical adherence problem that doesn't exist in controlled research settings.

This is also why experienced researchers pair GHRP-2 with CJC-1295 (no DAC) instead of the DAC version. Both clear within 2 hours, creating a sharp, quantifiable GH pulse. Stack them with the long-acting DAC modification and you lose the ability to measure discrete effects. The signal blurs into continuous low-level elevation. For mechanistic studies, short half-life peptides are non-negotiable.

How Research Teams Use Adamax's Clearance Profile

The 30-minute plasma window shapes every aspect of study design. Blood sampling protocols for GH measurement typically run 0, 15, 30, 60, 90, and 120 minutes post-injection. By the 120-minute mark, both Adamax and the GH pulse have resolved. Baseline is re-established without waiting days for washout. This allows same-day crossover comparisons (morning dose A, evening dose B) that would be impossible with longer-acting compounds.

Timing relative to meals matters more with short-acting peptides. GHRP-2 administered in a fasted state produces 40–60% higher GH peaks than the same dose given postprandially, because elevated glucose and insulin blunt ghrelin receptor sensitivity. Research teams studying metabolic interactions dose Adamax at least 3 hours after the last meal and delay feeding for 30–60 minutes post-injection to capture maximum effect. The short half-life makes this practical. Participants aren't fasting for 12-hour stretches to avoid carryover.

Our team at Real Peptides has seen this in action across labs running comparative secretagogue studies. The researchers who get the cleanest, most reproducible GH response curves are the ones who respect the 30-minute clearance. They time doses precisely, control meal timing rigorously, and don't assume "close enough" on refrigeration. Peptide research is unforgiving of sloppiness, and short-half-life compounds amplify every variable.

Adamax's rapid elimination also makes it safer for exploratory dose-escalation studies. If an unexpectedly high dose triggers side effects (flushing, transient hypoglycemia, water retention), those effects resolve within hours rather than persisting for days. This isn't a clinical use case. It's a research safety consideration when testing novel combinations or dose ranges.

The clearance profile also explains why GHRP-2 doesn't suppress endogenous GH production the way exogenous GH does. Because Adamax mimics natural pulsatile signaling and clears before the next endogenous pulse, it doesn't trigger negative feedback loops. Studies using GHRP-2 for 12+ weeks show no reduction in baseline GH or IGF-1. The system treats it as augmentation, not replacement. Longer-acting secretagogues can suppress endogenous pulses if dosed improperly, creating a rebound suppression when discontinued.

If you're comparing Adamax to other tools in the Real Peptides catalog, consider what your study design requires. Need sustained elevation? MK-677 with its 4–6 hour half-life and once-daily oral dosing fits better. Need discrete, measurable pulses with no carryover between doses? That's exactly what GHRP-2's 30-minute window was designed for.

The plasma half-life of Adamax isn't a technical footnote. It's the central constraint that defines how the peptide can and should be used. Researchers who treat it like a long-acting compound (dosing once daily, storing reconstituted vials at room temperature, ignoring meal timing) get inconsistent results and blame the peptide. Those who design protocols around the 30-minute clearance get reproducible, publication-quality data every time.

What's the half-life of Adamax? Twenty-five to thirty minutes. And that precision. Chemical, pharmacokinetic, and experimental. Is why it remains the reference standard for acute GH secretion research more than two decades after its initial characterization.